ClinicalTrials.gg
CompletedNCT01806363Updated Feb 25, 2014

Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone

A Phase 1 interventional study of Telmisartan 80mg and Chlorthalidone 25mg in Hypertension, sponsored by HanAll BioPharma Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-25.

Sponsored by HanAll BioPharma Co., Ltd. (part of Daewoong Pharmaceutical Co. LTD.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Planned enrollment
78th of 99
60 · median 184
Started
2012
with 1 other
Phase 1
15 of 99
none open now
Registered
47th of 99
by date

Among the 99 studies testing telmisartan in Hypertension, this one is the 78th largest by planned enrollment, is one of 2 that started in 2012, is one of 15 in phase 1, and was the 47th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 20 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

Clinical trial to evaluate the pharmacokinetic interactions and safety between telmisartan and chlorthalidone.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Pharmacokinetics
  • Safety
  • Male
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects
  2. Age(yr)between 20 and 50
  3. Signed written

Exclusion criteria

Exclusion Criteria:

  1. Known to investigator product, thiazide, sulphonamide and other drugs or additive.
  2. History of any siginificant Sickness, Cardiovascular, Respiratory, Renal, Endocrine, Neurological, Psychic, Cancer, Gasstrointestinal, Hematologic.
  3. History of drug and/or alcohol abuse
  4. Over 10 tobaccos a day
  5. Other condition which in the opinion of the investigator preclude enrollment into the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Part A: Telmisartan, Chlorthalidone + Telmisartan

    telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally

    Drug: Telmisartan 80mg · Drug: Chlorthalidone 25mg

  • Active comparator
    Part B: Chlorthalidone, Chlorthalidone + Telmisartan

    telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally

    Drug: Telmisartan 80mg · Drug: Chlorthalidone 25mg

06

What researchers measure

Primary outcomes

  1. Part A : AUC, Cmax of Telmisartan

    Time frame: Over a 24-hour sampling period

  2. Part B : AUC, Cmax of Chlorthalidone

    Time frame: Over a 24-hour sampling period

Secondary outcomes

  1. Part A : Cmin, tmax, CL/F of Telmisartan

    Time frame: Over a 24-hour sampling period

  2. Part B : Cmin, tmax, CL/F of Chlorthalidone

    Time frame: Over a 24-hour sampling period

07

Study locations

1 site
  • Kyungpook national university hospital Clionical center
    Daegu, Gyeongsangbuk-do 700-721, Korea, Republic of
08

References and documents

Publications

  • Seong SJ, Lim MS, Lee J, Ohk B, Gwon MR, Kim BK, Kim HJ, Yang DH, Lee HW, Kang WY, Yoon YR. Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects. Clin Drug Investig. 2016 Aug;36(8):613-23. doi: 10.1007/s40261-016-0406-y. PubMed 27206575 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2013
First posted
Mar 7, 2013
Start
Nov 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Feb 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01806363
Responsible party
Sponsor
First posted
Mar 7, 2013
Start date
Nov 2012
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Feb 25, 2014

Study contacts

Young Ran Yoon, Associate Professor
principal investigator · KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL, CLINICAL TRIAL CENTER

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Chlorthalidone

Start the discussion